MEDS - Trxade Group Inc Stock Price, Fair Value and News

5.84USD+0.22 (+3.91%)Market Closed

Market Summary

USD5.84+0.22

Market Closed

3.91%

MEDS Stock Price

View Fullscreen

MEDS RSI Chart

MEDS Valuation

Market Cap

8.2M

Price/Earnings (Trailing)

-0.46

Price/Sales (Trailing)

0.99

Price/Free Cashflow

-5.16

MEDS Price/Sales (Trailing)

MEDS Profitability

Operating Margin

31.41%

Return on Equity

-3.3K%

Return on Assets

-142.57%

Free Cashflow Yield

-19.39%

MEDS Fundamentals

MEDS Revenue

Revenue (TTM)

8.3M

MEDS Earnings

Earnings (TTM)

-17.9M

Earnings Growth (Yr)

-1.2K%

Earnings Growth (Qtr)

-231.64%

Breaking Down MEDS Revenue

Last 7 days

1.4%

Last 30 days

-17.5%

Last 90 days

27.2%

Trailing 12 Months

26.7%

How does MEDS drawdown profile look like?

MEDS Financial Health

Current Ratio

0.24

MEDS Investor Care

Shares Dilution (1Y)

106.60%

Diluted EPS (TTM)

-10.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	9.3M	8.2M	8.3M	8.3M
2022	10.1M	11.5M	11.3M	10.3M
2021	18.0M	13.3M	9.5M	9.9M
2020	8.1M	12.8M	16.8M	17.1M
2019	4.5M	5.6M	7.0M	7.4M
2018	3.1M	3.2M	3.3M	3.8M
2017	2.8M	2.9M	3.0M	3.0M
2016	2.4M	2.7M	3.0M	3.2M
2015	1.9M	2.8M	4.1M	2.1M
2014	1.1M	1.2M	1.4M	1.5M
2013	0	0	0	955.9K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Trxade Group Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 05, 2024	patel prashant	acquired	-	-	150,000	interim cfo and director
Jan 05, 2024	ajjarapu surendra k	acquired	-	-	150,000	chairman and ceo
Jan 16, 2023	peterson michael l	acquired	-	-	100,000	-
Dec 30, 2022	newell a. jeffrey	acquired	-	-	237,186	-
Dec 13, 2022	huffman janet	acquired	-	-	50,000	cfo, pao, pfo
Sep 01, 2022	pope charles l	acquired	-	-	54,525	-
Sep 01, 2022	ajjarapu surendra k	acquired	-	-	51,724	ceo
Sep 01, 2022	patel prashant	acquired	-	-	8,620	president and coo
Sep 01, 2022	fell donald g.	acquired	-	-	54,525	-
Sep 01, 2022	huffman janet	acquired	-	-	21,551	cfo, pao, pfo

Which funds bought or sold MEDS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-51.45	-471	10,435	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-78.00	-	-%
May 14, 2024	Qube Research & Technologies Ltd	sold off	-100	-520	-	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	new	-	342,000	342,000	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	new	-	104,427	104,427	-%
May 13, 2024	UBS Group AG	new	-	2,519	2,519	-%
May 10, 2024	VANGUARD GROUP INC	new	-	148,972	148,972	-%
May 10, 2024	BlackRock Inc.	new	-	84,173	84,173	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	unchanged	-	40.00	82.00	-%

Are Funds Buying or Selling MEDS?

Are funds buying MEDS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MEDS

No. of Funds

Unveiling Trxade Group Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	65,502	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	977,103	SC 13G
Oct 19, 2022	patel prashant	22.4%	2,092,371	SC 13D/A
Oct 19, 2022	ajjarapu surendra k	24.5%	2,288,824	SC 13D/A
Jun 16, 2020	ajjarapu surendra k	28.8%	2,217,724	SC 13D/A
Apr 21, 2020	ajjarapu surendra k	31.4%	2,418,296	SC 13D/A
Oct 08, 2019	r.s.n., llc	7.7%	3e+06	SC 13G/A
Oct 08, 2019	r.s.n., llc	7.7%	3e+06	SC 13G/A

Recent SEC filings of Trxade Group Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	PRE 14A	PRE 14A
May 15, 2024	NT 10-Q	NT 10-Q
May 03, 2024	10-K/A	Annual Report
Apr 22, 2024	10-K	Annual Report
Apr 02, 2024	NT 10-K	NT 10-K
Mar 06, 2024	8-K	Current Report
Feb 26, 2024	SEC STAFF ACTION	SEC STAFF ACTION
Feb 16, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Trxade Group Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Trxade Group Inc News

Latest updates

Trxade Group Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-	-	-	2,251	2,248	1,331	2,400	3,279	3,240	2,388	2,550	1,898	3,053	1,994	6,332	6,593	2,203	1,696	2,311	1,916	1,513	1,294
Gross Profit	-233.7%	-2,278	1,705	1,645	1,557	1,578	1,372	1,171	1,336	1,240	1,281	841	1,383	133	1,929	2,005	1,640	1,250	1,311	1,163	1,147	847
Operating Expenses	44.4%	3,681	2,550	1,990	1,904	2,422	1,591	2,274	2,304	2,023	2,577	3,411	2,028	-	-	-	-	-	-	-	-	-
S&GA Expenses	145.2%	1,505	614	305	377	279	230	547	651	-116	917	648	448	1,713	1,783	2,540	1,452	1,239	1,133	1,031	975	1,157
Interest Expenses	179.4%	703	252	181	62.00	196	130	9.00	1.00	2.00	6.00	9.00	7.00	7.00	7.00	7.00	8.00	6.00	13.00	16.00	18.00	18.00
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-231.6%	-11,690	-3,525	-1,974	-677	-908	-503	-1,112	-965	-784	-1,301	-2,578	-651	-2,312	138	-542	180	-495	28.00	58.00	125	-187
Net Income Margin	-169.8%	-2.16*	-0.80*	-0.43*	-0.31*	-0.30*	-0.30*	-0.36*	-0.56*	-0.54*	-0.72*	-0.41*	-0.19*	-	-	-	-	-	-	-	-	-
Free Cashflow	37.4%	-386	-617	315	-945	1,216	-590	-1,192	-1,014	-440	-752	-705	-724	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-42.1%	12,533	21,654	3,745	4,038	3,710	4,480	5,672	5,840	5,766	5,514	6,896	9,693	9,793	11,854	11,732	11,474	5,571	5,855	5,855	3,299	2,228
Current Assets	-50.4%	2,753	5,548	2,095	2,386	2,093	2,373	3,347	3,597	4,374	5,189	6,536	9,155	9,221	10,643	10,123	9,795	3,803	4,315	1,952	1,491	1,466
Cash Equivalents	346.4%	152	34.00	746	1,194	1,095	322	962	1,871	3,123	3,572	4,520	5,209	5,920	6,648	4,151	7,701	2,872	3,359	540	534	870
Inventory	-100.0%	968*	3,027	161	126	66.00	76.00	127	274	56.00	95.00	139	470	1,258	1,647	1,819	368	57.00	63.00	547	62.00	80.00
Net PPE	-3.8%	277	288	60.00	62.00	65.00	68.00	71.00	74.00	99.00	13.00	15.00	161	162	150	151	197	175	11.00	13.00	14.00	15.00
Goodwill	-100.0%	-	5,129	-	-	-	-	-	-	-	-	-	-	-	726	726	726	726	726	726	726	726
Liabilities	18.8%	11,991	10,094	5,040	3,383	3,367	3,333	3,868	2,953	1,996	897	1,109	1,492	1,114	1,027	1,581	1,837	1,431	1,964	2,338	2,081	1,383
Current Liabilities	27.1%	11,556	9,092	4,263	2,550	2,147	2,061	2,546	1,596	926	655	861	1,238	842	535	720	951	521	956	1,085	808	860
Shareholder's Equity	-95.3%	542	11,560	-	655	763	1,357	1,805	2,888	3,770	4,617	5,787	8,202	8,679	10,827	10,151	9,637	4,140	3,891	1,340	1,218	845
Retained Earnings	-54.4%	-33,245	-21,529	-21,900	-19,900	-19,719	-18,800	-18,300	-17,213	-16,247	-15,463	-14,161	-11,583	-10,931	-8,619	-8,757	-8,215	-8,395	-7,900	-7,927	-7,985	-8,111
Additional Paid-In Capital	2.1%	33,788	33,090	20,586	20,560	20,483	20,193	20,112	20,083	20,018	20,080	19,948	19,785	19,611	19,446	18,909	17,852	12,536	11,790	9,268	9,204	8,956
Shares Outstanding	10.5%	905	819	683	681	626	547	545	545	544	544	541	540	540	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-420	-42.43	-16.69	18.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	11,457	-	-	-	16,922	-	-	-	16,922	-	-	-	21,541	-	-	-	2,653	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	35.9%	-386	-603	329	-931	2,557	-576	-1,178	-1,000	-426	-738	-691	-710	-715	2,483	-3,571	-410	-182	404	46.00	-125	42.00
Cashflow From Investing	-102.2%	-418	-207	-51.80	333	314	-55.73	-280	23.00	-	-	-	-	-14.00	-	-	-23.50	-82.25	-	-40.00	-210	-
Cashflow From Financing	1496.6%	1,835	115	-725	681	-28.19	-7.86	550	-274	-	-210	-	-	1.00	13.00	22.00	5,264	-222	2,415	-	166*	500

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MEDS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 8,272,214	$ 10,250,168
Cost of sales	5,673,957	4,730,897
Gross Profit	2,598,257	5,519,271
Operating Expenses:
Loss on inventory investment		875,250
Wage and salary expense	2,698,178	3,581,089
Professional fees	1,466,567	466,735
Accounting and legal expense	1,534,377	829,751
Technology expense	1,376,908	993,185
General and administrative	2,785,633	1,689,230
Total operating expenses	9,861,663	8,435,240
Operating Loss	(7,263,406)	(2,915,969)
Nonoperating Income (Expense)
Change in fair value of warrant liability	(148,420)	825,544
Interest income	4,198	20,989
Goodwill impairment	(5,129,115)
Gain on disposal of asset		2,200
Other income	14,543
Interest expense	(1,198,346)	(336,206)
Total nonoperating income (expense)	(6,457,140)	512,527
Net loss from continuing operations	(13,720,546)	(2,403,442)
Net loss on discontinued operations	(4,123,028)	(1,506,426)
Net Loss	(17,843,574)	(3,909,868)
Net loss attributable to TRxADE Health, Inc.	(17,843,574)	(3,472,099)
Net loss attributable to non-controlling interests		$ (437,769)
Net loss per common share from continuing operations
Basic	$ (17.96)	$ (3.48)
Diluted	(5.76)	(3.47)
Net loss per common share from discontinued operations
Basic	(5.40)	(2.67)
Diluted	(1.73)	(2.66)
Net loss attributable to common stockholders
Basic	(23.35)	(6.15)
Diluted	$ (7.49)	$ (6.13)
Weighted average common shares outstanding
Basic	764,058	564,862
Diluted	2,381,443	566,609

MEDS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash	$ 151,908	$ 1,094,894
Accounts receivable, net	821,804	629,921
Inventory	968	65,523
Prepaid assets	107,774	104,461
Notes receivable	1,300,000
Other receivables	370,608
Current assets of discontinued operations		198,324
Total Current Assets	2,753,062	2,093,123
Property, plant and equipment, net	277,009	65,214
Intangible assets and capitalized software, net	8,962,688
Security deposits	10,531	49,029
Operating lease right-of-use assets	529,623	1,051,815
Noncurrent assets of discontinued operations		450,845
Total Assets	12,532,913	3,710,026
Current Liabilities
Accounts payable	2,082,054	527,984
Accrued liabilities	400,987	271,230
Other current liabilities	70,310	67,517
Contingent funding liabilities	1,246,346	108,036
Lease liabilities – current portion	139,705	196,872
Notes payable – current portion	6,530,000	166,667
Warrant liability	736,953	588,533
Purchase price payable	350,000
Current liabilities of discontinued operations		219,952
Total Current liabilities	11,556,355	2,146,791
Long Term Liabilities
Lease liabilities – net of current portion	409,205	887,035
Notes payable	25,000	333,333
Total Liabilities	11,990,560	3,367,159
Stockholders’ Equity
Preferred stock value
Common stock, $0.00001 par value; 100,000,000 shares authorized; 905,008, and 626,247 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	9	6
Additional paid-in capital	33,788,284	20,482,666
Retained deficit	(33,245,940)	(19,719,536)
Total TRxADE Health, Inc stockholders’ equity	542,353	763,136
Non-controlling interest in subsidiary		(420,269)
Total stockholders’ equity	542,353	342,867
Total Liabilities and Stockholders’ Equity	$ 12,532,913	$ 3,710,026

About Trxade Group Inc

TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which offers price transparency, purchasing capabilities, and other value-added services; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Lutz, Florida.

CEO	Mr. Surendra K. Ajjarapu
WEBSITE	trxadehealth.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	33

Trxade Group Inc Frequently Asked Questions

What is the ticker symbol for Trxade Group Inc? What does MEDS stand for in stocks?

MEDS is the stock ticker symbol of Trxade Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Trxade Group Inc (MEDS)?

As of Fri May 17 2024, market cap of Trxade Group Inc is 8.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MEDS stock?

You can check MEDS's fair value in chart for subscribers.

What is the fair value of MEDS stock?

You can check MEDS's fair value in chart for subscribers. The fair value of Trxade Group Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Trxade Group Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MEDS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Trxade Group Inc a good stock to buy?

The fair value guage provides a quick view whether MEDS is over valued or under valued. Whether Trxade Group Inc is cheap or expensive depends on the assumptions which impact Trxade Group Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MEDS.

What is Trxade Group Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MEDS's PE ratio (Price to Earnings) is -0.46 and Price to Sales (PS) ratio is 0.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MEDS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Trxade Group Inc's stock?

In the past 10 years, Trxade Group Inc has provided 0.806 (multiply by 100 for percentage) rate of return.